Skip to main content
    P

    ProKidney Corp. (PROK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    -0.01 (-0.48%)

    Market Cap: $417.20M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    ProKidney Corp. (PROK) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    ProKidney reported revenue of $893.00K for the fiscal year ended Dec 31, 2025, up 1075.0% from the year before. That year, net income was -$151.61M with a net margin of -16977.8%, operating cash flow was -$120.12M and free cash flow was -$135.31M. The quarter ended Sep 30, 2026 had revenue of $174.00K and net income of -$51.79M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$893.00K+1075.0%100.0%-18477.8%-16977.8%
    Dec 2024$76.00KN/A100.0%-241678.9%-214914.5%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$893.00K$76.00K$0$0$0$0N/A
    Gross profit$893.00K$76.00K$0$0$0$0N/A
    Research and development$114.12M$127.67M$106.71M$82.07M$46.26M$21.04M$75.22M
    Operating income-$165.01M-$183.68M-$151.52M-$153.01M-$55.11M-$27.02M-$79.38M
    Net income-$151.61M-$163.34M-$135.45M-$148.13M-$55.15M-$26.75M-$79.61M
    EBITDA-$158.43M-$178.24M-$147.67M-$149.97M-$53.13M-$26.06M-$18.29M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$174.00K$150.00K$226.00K$225.00K$217.00K$221.00K$230.00K$76.00K$0$0$0$4.49M
    Gross profit$174.00K$150.00K$226.00K$225.00K$217.00K$221.00K$230.00K$76.00K$0$0$0$3.46M
    Operating income-$53.76M-$48.37M-$44.93M-$45.37M-$38.54M-$39.71M-$41.39M-$51.57M-$48.97M-$43.06M-$40.08M-$24.21M
    Net income-$51.79M-$46.44M-$42.62M-$40.85M-$35.84M-$36.97M-$37.95M-$48.48M-$41.05M-$38.47M-$35.33M-$21.72M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.07M by $107.47M. Shareholder equity was negative, at -$1.01B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$335.57M$441.07M$420.55M$518.00M$40.30M$16.70M$19.61M
    Current assets$280.68M$395.88M$374.15M$504.72M$27.27M$5.58M$15.42M
    Cash and equivalents$108.54M$99.12M$60.65M$490.25M$20.56M$4.58M$15.23M
    Total liabilities$34.78M$39.44M$29.22M$13.06M$13.38M$6.84M$3.72M
    Short-term debt$1.07M$765.00K$803.00K$493.00K$267.00K$225.00K$102.00K
    Shareholder equity-$1.01B-$994.95M-$1.10B-$1.10B$26.92M$9.86M$15.88M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$210.28M$249.02M$292.78M$335.57M$351.61M$372.13M$406.06M$441.07M$474.79M$499.16M$387.76M$420.55M
    Total liabilities$33.30M$26.18M$29.68M$34.78M$33.27M$32.68M$36.08M$39.44M$31.32M$26.80M$24.73M$29.22M
    Cash and equivalents$81.36M$74.87M$101.89M$108.54M$95.32M$84.94M$97.81M$99.12M$108.09M$214.51M$84.39M$60.65M
    Shareholder equity-$906.85M-$883.53M-$1.02B-$1.01B-$1.01B-$1.00B-$998.55M-$994.95M-$979.71M-$972.37M-$1.10B-$1.10B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$120.12M-$126.35M-$90.07M-$77.09M-$50.30M-$25.18M-$76.81K
    Capital expenditures$15.20M$29.51M$34.20M$1.85M$5.19M$5.46M$1.30K
    Free cash flow-$135.31M-$155.86M-$124.27M-$78.94M-$55.49M-$30.64M-$78.11K
    Share repurchases$0$0$9.50M$0$0N/AN/A
    Investing cash flow$103.97M$20.41M-$329.98M-$1.74M-$5.19M-$5.46M-$2.97K
    Financing cash flow$25.57M$144.41M-$9.55M$548.52M$71.47M$19.99M$20.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$38.65M-$40.37M-$41.68M-$32.51M-$26.60M-$31.42M-$29.59M-$24.17M-$29.24M-$38.29M-$34.65M-$25.38M
    Capital expenditures$1.23M$3.83M$3.79M$5.75M$5.20M$3.11M$1.14M$25.51M$2.40M$636.00K$960.00K$1.57M
    Free cash flow-$39.88M-$44.21M-$45.47M-$38.27M-$31.79M-$34.53M-$30.73M-$49.68M-$31.64M-$38.93M-$35.61M-$26.96M
    Last 12 quarters

    Frequently Asked Questions About PROK

    What is ProKidney's annual revenue?

    ProKidney reported revenue of $893.00K for the fiscal year ended Dec 31, 2025.

    How fast is ProKidney's revenue growing?

    Revenue was up 1075.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is ProKidney profitable?

    No. ProKidney reported net income of -$151.61M for the fiscal year ended Dec 31, 2025, with a net margin of -16977.8%.

    How much free cash flow does PROK generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$120.12M minus capital expenditures of $15.20M produced free cash flow of -$135.31M.

    How much debt does ProKidney have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.07M and cash and equivalents of $108.54M.